The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Vitry
Agnes I
AI
Hurley
Eve
E
D015982:Bias; D016265:Conflict of Interest; D032921:Consensus; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004345:Drug Industry; D011307:Drug Prescriptions / Q000592:standards*; D017723:Drug Utilization Review; D019317:Evidence-Based Medicine; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D017410:Practice Guidelines as Topic / Q000592:standards*; D011451:Prostaglandin-Endoperoxide Synthases; D012449:Safety
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases